06160 BEIGENE
- 99.900
- -0.050-0.05%
BEIGENE News
BeiGene (06160)'s total revenue for the first quarter reached US$752 million, up 68% year-on-year
BeiGene (06160) announced results for the first quarter of 2024, with total revenue reaching US$752 million, up 68% year on year; of these, product revenue reached US$747 million, up 82% year on year. Gross profit was approximately US$627 million, up 71.23% year over year. The adjusted operating loss was approximately US$147 million, a decrease of 47% over the previous year. R&D expenses were approximately US$460 million, an increase of 13% over the previous year. The net loss was approximately US$251 million, a year-on-year decrease of 27.9%.
BeiGene (6160.HK): European and American PD-1 releases zebutinib to open overseas markets
Core products are released at a high speed and maintain the “gain” rating. The company achieved product revenue of US$747 million in 2024Q1, +82.0% year over year, showing a rapid growth trend driven by zebutinib and tirelizumab; 2024Q1
BeiGene Shenzhou Co., Ltd. 2024 First Quarter Report
BeiGene (688235.SH)'s first quarter revenue surged 74.8% to 5.359 billion yuan, R&D investment increased 18.1% to 3.328 billion yuan
BeiGene (688235.SH) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Express News | BeiGene: Net profit loss of 1.908 billion yuan in the first quarter of 2024
Express News | BeiGene: Multiple pipelines are expected to enter clinical trials. Product revenue is expected to continue to grow in 2024
BeiGene's Soaring Sales and Path to Profitability Reinforce Buy Rating
Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Is Maintained at Buy by TD Cowen
TD Cowen: Maintaining the BGNE.US (BGNE.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $236.00 to $254.00.
TD Cowen: Maintaining the BGNE.US (BGNE.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $236.00 to $254.00.
TD Cowen Maintains Buy on BeiGene, Raises Price Target to $254
TD Cowen analyst Yaron Werber maintains BeiGene with a Buy and raises the price target from $236 to $254.
BeiGene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 51.3% TD Cowen $236 → $254 Maintains Buy 04/24/2024 40.58% TD Cowen $235 → $236 Maintains Buy 0
According to the Dongguan Securities Research Report, the main reason for the year-on-year decline in net profit loss due to BeiGene (688235.SH) in the first quarter was that the company achieved rapid growth in product revenue, which increased 74.8% year
According to the Dongguan Securities Research Report, the main reason for the year-on-year decline in net profit loss due to BeiGene (688235.SH) in the first quarter was that the company achieved rapid growth in product revenue, which increased 74.8% year on year faster than the company's operating expenses. The company's Q1 core products continued to grow rapidly. The company's product revenue for the first quarter of 2024 was 5.325 billion yuan, up 89.6% year-on-year from the previous year. The increase in product revenue was mainly due to the increase in sales of the company's self-developed products Baiyue Ze, Baizean, and Amgen authorized products. The company continues to promote the globalization of self-developed drugs and will continue to expand Baiyueze's global pharmaceuticals
Research Report Nuggets丨Dongguan Securities: BeiGene Shenzhou Q1 core products continue to be released, maintaining the “increase in holdings” rating
GLONGHUI, May 9 | According to the Dongguan Securities Research Report, BeiGene Shenzhou (688235.SH)'s net profit loss in the first quarter declined year on year, mainly due to the rapid growth of the company's product revenue, which increased 74.8% year on year, faster than the company's operating expenses. The company's Q1 core products continued to be released and achieved rapid growth. The company's product revenue for the first quarter of 2024 was 5.325 billion yuan, up 89.6% year on year. The increase in product revenue was mainly due to increased sales of the company's self-developed products Baiyue Ze, Baizean, and Amgen authorized products. The company continues to promote independent drug development around the world
New Risks Emerge for BeiGene: Investors Alerted to Material Updates in Financial Disclosures
BeiGene (688235) 2024 Quarterly Report Review: Continued Release of Core Products
Event: The company released its report for the first quarter of 2024. In the first quarter of 2024, the company achieved operating income of 5.359 billion yuan, an increase of 74.8% over the previous year; realized net profit attributable to shareholders of listed companies - 1,908 billion yuan; realized deductions
Hong Kong Stock Afternoon Review | The three major indices rose sharply, domestic housing stocks and biotech stocks strengthened, Shimao Group rose more than 42%, and Ziding Pharmaceutical rose nearly 17%
Science and network stocks generally rose; Meituan rose more than 4%, and Bilibili rose nearly 3%; shipping stocks generally rose, with COSCO Maritime Control rising by more than 6%, and Orient Overseas International rising more than 5%.
Bank Rating | Lyon: Raising BeiGene's Target Price to HK$139.7 to Reiterate “Buy” Rating
Glonghui, May 9 | Lyon published a research report showing that BeiGene's sales for the first quarter of fiscal year 2024 increased 67.9% year-on-year, and its performance exceeded market expectations. The bank believes that sales of BTK inhibitors independently developed by BeiGene are still the main driving force for its performance, with sales of related inhibitors increasing by 131.1% year on year. According to the bank's statistics, the market share of these inhibitors in the US has increased to 24.1%, while the market share for the third quarter and fourth quarter of last year was 19.1% and 21.2%, respectively. The bank also believes that the progress of the company's BCL-2 and BTK CDAC products this year is worth watching
Direct change | BeiGene opened more than 5% higher, total revenue for the first quarter increased by nearly 70% year-on-year, and Baiyuze's global growth was strong
BeiGene (06160) opened more than 3% higher. As of press release, it rose 3.38% to HK$98, with a turnover of HK$2,334,300.
Hong Kong A change丨BeiGene AH shares surged by more than 5%, and Q1 product revenue surged 82% year over year
Glonghui, May 9 | BeiGe-U (688235.SH) once rose more than 5% to 141.3 yuan, and H shares once rose more than 7% to HK$101.9. According to the news, BeiGene announced last night that its total revenue for the first quarter was 752 million US dollars, up 68% year on year, of which product revenue reached 747 million US dollars, up 82% year on year. This was mainly due to Baiyueze's global sales of US$489 million. Sales in the US and Europe were US$351 million and US$67 million, respectively, up 153 percent and 243 percent year-on-year, respectively. Thanks to a significant increase in global revenue, according to antineoplastic drugs
Analysis
Price Target
No Data
